Abstract:Background: Primary triple-negative breast cancer (TNBC) is influenced by hypoxic microenvironments that promote metastasis and paclitaxel (PTX) resistance. However, few studies have attempted to understand how hypoxia promotes metastasis and drug resistance and provide a solution to these problems, especially in TNBC. Methods: Transcriptome sequencing of TNBC cells under hypoxic conditions was performed to identify C1QBP. The mechanism of HIF-1α induced C1QBP under both hypoxia and normoxia were investigated by ChIP-qPCR. Next the role of C1QBP in mediating metastasis and chemoresistance to PTX and regulating VCAM-1 were studied by in vitro and in vivo experiments. Then the anti-cancer effect of C1QBP inhibition in hypoxic environment was investigated. Furthermore, TCGA database and clinical tissue microarrays in our cohort were used to verify the correlation of C1QBP with the expression of HIF-1α, VCAM-1, and p65. Results: Here, we report that hypoxia-induced HIF-1α upregulated the expression of C1QBP; the inhibition of C1QBP notably blocked metastasis of TNBC cells and increased their sensitivity to PTX under hypoxic conditions in vitro and in vivo. Depletion of C1QBP decreased VCAM-1 expression by reducing p65 protein levels in the nucleus and, remarkably, suppressed the activation of hypoxia-induced PKC–NF-κβ signaling. Moreover, tissue microarray and immunohistochemical staining showed a positive correlation between the protein levels of C1QBP and that of p65 and VCAM-1 in breast cancer patients (especially TNBC). The analysis from TCGA database further confirmed the correlation between the mRNA levels of C1QBP, HIF-1α, and VCAM-1 in TNBC patients. Conclusions: Hypoxia-induced HIF-1α upregulates C1QBP expression of TNBC cells. Deregulated C1QBP may inhibit hypoxia-induced metastasis and PTX resistance along with reducing the activation of the PKC–NF-κβ–VCAM-1 axis. Targeting C1QBP in the presence of PTX may be a potential therapeutic against hypoxia-induced metastatic or drug resistant TNBC. Funding Statement: Haiyan Fund Project of Harbin Medical University Cancer Hospital (Grant number: JJQN 2018-06); Health Committee Fund Project of Heilongjiang Province (Grant number: 2019-056); National Natural Science Foundation of China, Grant/Award Numbers: 81972706; National Natural Science Foundation of China, Grant/Award Numbers: 81602639; National Natural Science Foundation of China, Grant/Award Numbers: 81602323; National Natural Science Foundation of China, Grant/Award Numbers: 81872149; Heilongjiang postdoctoral fundation (LBH-Z18222). Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation, Grant/Award Number: YQ2019H027; 9. Wu Lien‐ the Science Foundation of Harbin Medical University, Grant/Award Number: WLD‐ QN1706; Young Elite Training Foundation Grant of Harbin Medical University Cancer Hospital, Grant/Award Number: JY2016‐ 02; Distinguished Young Scholars of Harbin Medical University Cancer Hospital, Grant/Award Number: JCQN2018‐ 03.Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: The Medical Ethics Committee approved this study and all the relevant information was provided to the patients who were willing to participate in the study.

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

Abstract P4-08-23: ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

Effector T Cells under Hypoxia Have an Altered Transcriptome Similar to Tumor-Stressed T Cells Found in Non-Responsive Melanoma Patients

Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy

Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment

Identification of Hypoxia-ALCAMhigh Macrophage- Exhausted T Cell Axis in Tumor Microenvironment Remodeling for Immunotherapy Resistance

Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway

The regulation of immune checkpoints by the hypoxic tumor microenvironment

Hypoxia: A Key Feature of the Tumor Microenvironment Triggers Several Mechanisms of Evasion from Natural Killer and Cytotoxic T Lymphocytes Surveillance

Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer

Respiratory Hyperoxia Reverses Immunosuppression by Regulating Myeloid-Derived Suppressor Cells and PD-L1 Expression in a Triple-Negative Breast Cancer Mouse Model.

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α

Hypoxia-Mediated C1QBP Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates VCAM-1 Expression Via Canonical Nf-Κβ Signaling

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

Regulation of hypoxia microenvironment on programmed death ligand 1 expression and immune response in triple negative breast cancer

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

Hypoxic Memory Mediates Prolonged Tumor Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression

HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer

Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways

Hypoxic memory of tumor intrinsic type I interferon suppression promotes breast cancer metastasis